Roche Holding AG said adding Tecentriq, or atezolizumab, to its existing medicines Zelboraf and Cotellic reduced the risk of disease progression or death in patients with a certain type of skin cancer.
The company and its unit Genentech Inc. studied the medicine in a late-stage study called IMspire150, which met its primary endpoint of improving progression-free survival when compared to placebo. The phase 3 trial enrolled previously untreated melanoma patients with the BRAF V600 mutation whose disease had spread to other parts of the body or could not be removed through surgery.
Roche co-developed Cotellic, or cobimetinib, with Exelixis Inc. A combination of Tecentriq and Cotellic previously failed to extend the lives of patients with untreated advanced melanoma who have no known mutation in their BRAF V600 gene.
Zelboraf is also known as vemurafenib.